site background
Skip to content
Ivy Brain Tumor Center
Trial EligibilityDonate
Main Menu
  • Physicians
  • Industry
  • Ivy Blog
Talk to an Ivy Navigator
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Clinical Trials
    • Current Trials
      • Temsirolimus in Recurrent High-Grade Glioma
      • SONODYNAMIC THERAPY IN RECURRENT GLIOBLASTOMA
      • AZD1390 FOR RECURRENT GLIOBLASTOMA
      • SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA
      • NIRAPARIB FOR NEWLY DIAGNOSED GLIOBLASTOMA
      • PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
      • ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
      • INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA
      • RIBOCICLIB FOR RECURRENT GLIOBLASTOMA
      • RIBOCICLIB FOR RECURRENT MENINGIOMA
    • What is a Phase 0 Trial?
    • Why Ivy Clinical Trials?
    • What We Treat
      • Gliomas
      • Brain Metastases
      • Meningiomas
      • Ependymomas
      • Craniopharyngiomas
      • Pineal-Region Tumors
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
      • Lodging
      • Transportation
    • Patient Support
    • FAQs
    • Share Your Story
  • Research
    • Scientific Cores
    • Laboratories
      • Mehta Laboratory
      • Tovmasyan Laboratory
      • Tien Laboratory
      • Mirzadeh Laboratory
    • Certifications
    • Preclinical Work
    • Industry Collaboration
    • Published Research
    • Ivy Center Seminar Series
  • About
    • Team
      • Administration
      • Business Operations
      • Clinical Operations
      • Communications
      • Preclinical and Translational Science
      • Clinicians
    • New Ivy Headquarters
    • It’s personal
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us
  • ESPAÑOL

Talk to an Ivy Navigator

602-406-8605
Home » About » Team » Michelle Felicella, MD
Person Placeholder
  • phone:(602) 406-3402
  • Send Email

Michelle Felicella, MD

Neuropathology

Dr. Michelle Felicella is a neuropathologist and surgical pathologist at the Barrow Neurological Institute. She is board certified in neuropathology by the American Board of Pathology. Dr. Felicella’s expertise includes the pathological diagnosis of brain and spinal tumors. Dr. Felicella completed her residency in anatomic and clinical pathology at University of Vermont Medical Center, a clinical fellowship in neuropathology at the University of California at San Francisco (UCSF), and a research fellowship in neuropathology at the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Felicella’s research interests include molecular genomics of central nervous system tumors and new clinical applications of diagnostic and prognostic markers in the laboratory. As a co-investigator at the Ivy Brain Tumor Center, Dr. Felicella is a key member of our Phase 0 clinical trials team and is particularly engaged in our pharmacodynamics assessments of new drug effects.

Arial shot of the Ivy Brain Tumor Center
Ivy Brain Tumor Center
  • The Challenge
    • Current Standard of Care
    • Conventional Clinical Trials
  • Phase 0 Clinical Trials
    • Why Ivy Clinical Trials?
    • What We Treat
    • Brain Tumor Clinical Trials
  • Patients
    • Patient Stories
    • What to Expect
    • Planning Your Visit
    • Patient Support
    • FAQs
  • About
    • Team
    • Barrow Neurological Institute
    • The Ben and Catherine Ivy Foundation
    • Newsroom
    • Events
    • Donate
    • Careers
    • Contact Us

Stay Updated

Follow Us

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube

2910 North Third Avenue
Phoenix, Arizona 85013
(602) 406-6489
[email protected]
Mailing Address for Donations »

© Ivy Brain Tumor Center, 2023. All Rights Reserved.
  • Privacy Policy
  • Site Map
Important Notice

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device.